[Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy].
Due to good therapeutic results and few side-effects so-called "low-dose glucocorticoid therapy" (ldgc) with daily glucosteroid dosage below 10 mg prednisolone-equivalent has recently been recommended in managing polymyalgia rheumatica and giant cell arteritis. This fact is of important interest, since mean therapy time is often over a period of five years. An open-prospective study with 75 patients in a rheumatological unit was done in which different clinical histories were examined and glucosteroid side effects of 47 patients who had received therapy over six months were analyzed. Main side-effect shown was osteoporosis (n = 7), other known steroid-side effects were quite seldom (less than 5%). Dosage regimens and therapy monitoring criteria are proposed.
Hatz
H J
HJ
IV. Med. Abteilung/Rheumatologie und Immunologie, Städt. KH München-Bogenhausen.
Helmke
K
K
D000368:Aged; D000369:Aged, 80 and over; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D005260:Female; D013700:Giant Cell Arteritis / Q000175:diagnosis / Q000188:drug therapy*; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced; D011111:Polymyalgia Rheumatica / Q000175:diagnosis / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects
D005938:Glucocorticoids; D011239:Prednisolone
Polymyalgia rheumatica und Riesenzellarteriitis; Diagnostik und Nebenwirkungsprofil bei niedrig-dosierter Glukokortikoidlangzeittherapie.